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Introduction
Over three hundred million people live in
the United States, home of the world’s largest
healthcare industry. In the United States, $300
billion a year is spent on prescription drugs
alone, and that number is rising. Despite the
undisputed fact that pharmaceutical companies
have made significant contributions to health
care and in improving quality of life for patients,
they are regularly critiqued as one of the least
trusted industries, next to the nuclear industry,
in public opinion surveys.2 Numerous pharma-
ceutical companies commit crimes severe enough
to be ranked in the top 100 corporate criminals
list.3 However, when it comes time to prosecute
them, their punishments are a mild reprimand
for their crimes. Medications, and the industry
that governs their development, the pharma-
ceutical industry, are human creations made to
improve and extend our natural health bound-
aries and quality of life. However, what happens
when too much power is extended to a technolog-
2David Taylor, “The Pharmaceutical Industry and the Future of Drug Development”, Pharmaceuticals in the
Environment, 2015, 1-33.
3Mokhiber, Russell, and Robert Weissman. “Top 100 Corporate Criminals of the 1990s.” Mother Jones,
Mother Jones, 28 June 2017, www.motherjones.com/politics/1999/09/top-100-corporate-criminals-1990s/.
27
ical system* that holds control of our most basic
and vital human rights, namely that of health
and life? Pharmaceutical companies are often
deemed as the “thugs” of the medical industry
because, like giant banks on Wall Street, they
are accepted as too big to fail.4 Like many phar-
maceutical companies, Pfizer abuses the power
granted by the structure of the healthcare sys-
tem to illegally commercialize products at the
expense of a patient’s wellbeing without taking
full responsibility of their actions when caught.
This injustice causes societal implications, and
all participants that ought to be “winners” ben-
efitting from this technological system (e.g. pa-
tients, doctors, pharmaceutical companies, and
the healthcare industry) instead secure more
losses, ultimately becoming “losers” of the sys-
tem. However, solutions in restoring the image
of the pharmaceutical industry can generate the
necessary stubborn change.
This Investigation seeks to explore the neg-
ative societal implications of limited regulation
in unethical criminal acts of pharmaceutical gi-
ants and potential solutions to increase public
trust in Big Pharma. It does this by drawing
on literature from medical history, philosophy,
and sociology. This piece integrates ideas from
these disciplines by utilizing the ideas of an ex-
perienced physician and health journalist, an
emeritus sociology professor interested in socio-
technological systems, and an interdisciplinary
Harvard philosophy and technology studies pro-
fessor to better understand the ramifications
of America’s self-destructive health care system
and generate potential solutions to remedy its
grave impacts on society.
*Note: the term technological system is used
throughout this piece because medication and
drugs are considered to be pieces of technology
with the practical purpose of treatment, care,
and promotion of health. The pharmaceutical
industry is a system that employs drugs and
medications, as is in large part a participant of
the health care system.
Background
Pfizer researches, develops, and produces
vaccines and medications over a range of medi-
cal disciplines, including the widely known little
blue pill, Viagra. The global pharmaceutical gi-
ant was established and produced its first prod-
uct in 18495 and has since accumulated over $4
billion in fines.6 Pfizer’s fourth settlement over
illegal marketing activities was the largest por-
tion of the $4 billion. An historic $2.3 billion
settlement resolved the civil and criminal alle-
gations in fraudulent marking for the painkiller
Bextra, and other drugs including the antipsy-
chotic Geodon, the antibiotic Zyvox, and the
antiepileptic Lyrica.7 As of 2009, this settle-
ment was the largest criminal charge of any kind
imposed in the United States.8
Bextra was identified as part of a radical
class of painkillers known as cyclooxygenase 2
(COX-2) inhibitors, at twenty times the price of
ibuprofen, but intended to be safer than generic
drugs.9 In 2001, Bextra was proposed to hit
the market as an acute pain treatment after
surgery. The U.S. Food and Drug Adminis-
tration (FDA) approved Bextra for menstrual
cramps and arthritis but deemed it unsafe at
higher doses for acute surgical pain and for pa-
4Drew Griffin and Andy Segal, “Feds Found Pfizer too big to nail”, CNN Health, April 2, 2010,
http://www.cnn.com/2010/HEALTH/04/02/pfizer.bextra/.
5Pfizer Inc., “Pfizer Company History”, http://www.pfizer.com/about/history/all
6Pfizer Inc. and Subsidiary Companies, “Pfizer 2010 Financial Report”, 2010, 66-68,
http://www.pfizer.com/files/annualreport/2010/financial/financial2010.pdf.
7Office of Public Affairs, “Justice Department Announces Largest Health care fraud Settlement in Its History”,
The United States Department of Justice, September 2, 2009, https://www.justice.gov/opa/pr/justice-department-
announces-largest-health-care-fraud-settlement-its-history.
8“The Case Against Pfizer”, The Federal Bureau of Investigation, September 2, 2009,
https://archives.fbi.gov/archives/news/stories/2009/september/pfizer settlement 090209.
9Mark Ratner, “Pfizer settles largest ever fraud suit for off-label promotion”, Nature Biotechnology 27 (2009):
961-962.
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tients at high risk of heart attacks. With bil-
lions in profit at stake, Pfizer and its partner,
Pharmacia, neglected the approval of the FDA
and employed teams of sale managers across the
country to market Bextra to health care pro-
fessionals.10 To further incentivize prescription
orders from doctors, a multimillion dollar budget
intended for medical education was used instead
to illegally pay doctors as promotional speakers
and consultants for Bextra and other drugs.
The act of promoting drugs for unapproved
uses is called “off-label marketing” and it is
judged as a criminal offence because it can
severely harm the lives of patients, especially
those with dire health conditions.11 Even know-
ingly so, CNN Special Investigations Unit re-
ported that a scripted sales pitch from Pfizer
was emailed to sales representatives in Florida
which condoned sales up to a 40 mg dose, twice
what the FDA deemed to be safe.12 In court,
Pfizer pleaded that, “the company’s intent was
pure”.13 However, when Bextra was taken off
the market in April 2005, “more than half of its
$1.7 billion in profits had come from prescrip-
tions written for uses the FDA had rejected.”14
Consequently, while the intent behind produc-
ing Bextra was to provide another alternative
to improve the lives of patients suffering from
pain, marketing Bextra at harmful unapproved
dosages only harms these patients If more than
half of the earnings from Bextra came from off-
label marketing, it is hard to believe Pfizer pro-
moted Bextra with the patient’s best interest in
mind.
The Conviction and Settlement
The number of patient lives put at risk in-
creased with every sale of Bextra. Considering
this was Pfizer’s fourth settlement over fraudu-
lent marketing, the punishments for their crimes
should logically increase in severity to cripple
the company enough such that they learn their
lesson. However, with the following compli-
cated legalities of the case, Pfizer escaped severe
corporate punishment and even had difficulties
bearing the requirements of their favorable reso-
lution.
Any company convicted of serious health care
fraud faces automatic exclusion from Medicare
and Medicaid as the one of harshest forms of
corporate punishment. Doing so will prevent a
company from collecting compensation for the
products it provides to Medicare and Medicaid.
Prosecutors tried convicting Pfizer with the au-
tomatic exclusion clause that would lead to
Pfizer’s collapse. However, Pfizer’s general coun-
sel, Amy Schulman, urged: “the vast majority
of our employees spend their lives dedicated to
bringing truly important medications to patients
and physicians in an appropriate manner.”15
Therefore, in consideration of the Pfizer employ-
ees not involved in fraudulent activity, patients
relying on Pfizer products through Medicare and
Medicaid, and the losses for Pfizer shareholders,
Pfizer was given an exception from the auto-
matic exclusion condition.16 For redemption for
all prior cases of fraudulent marketing, Pfizer
was given a fourth chance.
Instead of imparting a criminal charge upon
Pfizer, prosecutors agreed to charge Pfizer
10Mark Ratner, “Pfizer settles largest ever fraud suit for off-label promotion”, Nature Biotechnology 27 (2009):
961-962.
11Erin Janssen, “Pfizer Settlement Makes History”, Journal of Health Care Compliance, December 2009, 33-36.
12Drew Griffin and Andy Segal, “Feds Found Pfizer too big to nail”, CNN Health, April 2, 2010,
http://www.cnn.com/2010/HEALTH/04/02/pfizer.bextra/.
13Drew Griffin and Andy Segal, “Feds Found Pfizer too big to nail”, CNN Health, April 2, 2010,
http://www.cnn.com/2010/HEALTH/04/02/pfizer.bextra/.
14Drew Griffin and Andy Segal, “Feds Found Pfizer too big to nail”, CNN Health, April 2, 2010,
http://www.cnn.com/2010/HEALTH/04/02/pfizer.bextra/.
15Gardiner Harris, “Pfizer Pays $2.3 Billion to Settle Marketing Case”, The New York Times, September 2,
2009, http://www.nytimes.com/2009/09/03/business/03health.html.
16Drew Griffin and Andy Segal, “Feds Found Pfizer too big to nail”, CNN Health, April 2, 2010,
http://www.cnn.com/2010/HEALTH/04/02/pfizer.bextra/.
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through its subsidiary, Pharmacia & Upjohn Co.
Inc. A subsidiary corporation is defined as one in
which a generally larger company, known as the
parent corporation owns all or most of its shares.
As the owner of the subsidiary, the parent cor-
poration controls the activities of the subsidiary.
Instead of a merger, forming a subsidiary may
be more beneficial to the parent company be-
cause the approval of the stockholders is not
required and the parent owns a controlling in-
terest with a smaller investment. The parent
and subsidiary remains as separate legal entities
and the subsidiary may produce goods and ser-
vices completely different from those produced
by the parent company.17 Pfizer owns Pharma-
cia & Upjohn Co. Inc. through inheritance in
owning Pharmacia & Upjohn LLC which owns
Pharmacia & Upjohn CO. LLC which then owns
Pharmacia & Upjohn Co. Inc. If Pfizer was the
parent, the company charged with the subsidiary
is the greatgreat-grandson.18 Pharmacia & Up-
john Co. Inc. was incorporated on March 27,
2007 in Delaware. This was the same day when
federal prosecutors and Pfizer lawyers battled
it out, which led to Pfizer pleading guilty for a
bribery case a few years prior to the Bextra case.
Thus, Pharmacia & Upjohn Co. Inc., the pro-
tective bodyguard against criminal charges for
Pfizer was born. The bribery case ended with
Pharmacia & Upjohn Co Inc. pleading guilty
for Pfizer, and Pharmacia was excluded from
Medicare while Pfizer was free to commercialize
through federally funded health programs. The
same pattern was observed in the Bextra case.
Pharmacia pleaded guilty without ever having
sold a single pill or dosage of Bextra, while Pfizer
was still permitted to sell its products to feder-
ally funded health programs. The subsidiary was
nothing more than a shell company protecting
Pfizer when it got caught in hot waters.19 Since
Pharmacia’s sole function was to take criminal
pleas for Pfizer, the impact of corporate punish-
ment was severely minimized.
Pfizer paid almost $1.2 billion for Bextra but
Pharmacia & Upjohn Co. Inc. was responsible
for the rest.20 Together, the fees total to $2.3
billion, a record fine for any crime.21 Preceding
the Bextra case, $1.2 billion was the largest sum
the federal government has ever collected, until
together, Pharmacia and Pfizer nearly doubled
it. However, to put the money into perspective,
even the total $2.3 billion collected amounts
to less than three weeks of sales at Pfizer.22
Therefore, although $2.3 billion seems like dev-
astating debt to pay, for a pharmaceutical gi-
ant like Pfizer, it may simply be spare pocket
change. Harvard Medical School health science
researcher and attorney, Aaron Kesselheim, wor-
ries that “settlements for fraud should do more
than punish a particular company. . . it should
send a message to the industry about what
are-or are not-reasonable practices. . . there’s a
big question as to whether these settlements
actually do that.”23 Corporate punishment is
meant to serve as a deterrent against criminal
misconduct, but the punishment for Pfizer was
essentially halved because they did not take full
responsibility for their crime. Instead, Pfizer
created an imaginary friend to take the fall for
them.
17“Subsidiary.” The Free Dictionary, Farlex, legal-dictionary.thefreedictionary.com/subsidiary.
18Drew Griffin and Andy Segal, “Feds Found Pfizer too big to nail”, CNN Health, April 2, 2010,
http://www.cnn.com/2010/HEALTH/04/02/pfizer.bextra/.
19David Tippie, “Collapse of Drugs Due to Wellness” (Lulu Com, 2010), 12
20Office of Public Affairs, “Justice Department Announces Largest Health care fraud Settlement in Its History”,
The United States Department of Justice, September 2, 2009, https://www.justice.gov/opa/pr/justice-department-
announces-largest-health-care-fraud-settlement-its-history.
21“The Case Against Pfizer”, The Federal Bureau of Investigation, September 2, 2009,
https://archives.fbi.gov/archives/news/stories/2009/september/pfizer settlement 090209.
22Gardiner Harris, “Pfizer Pays $2.3 Billion to Settle Marketing Case”, The New York Times, September 2,
2009, http://www.nytimes.com/2009/09/03/business/03health.html.
23Mark Ratner, “Pfizer settles largest ever fraud suit for off-label promotion”, Nature Biotechnology 27 (2009):
961-962.
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While Pfizer was settling the improper mar-
keting of Bextra and the three other medications
involved, the company was also in the midst of
bearing the expenses for marketing fraud with
regards to the epilepsy drug, Neurontin, from
2004,24 and federal charges in illegal promo-
tion of the growth hormone, Genotropin, from
2007.25 The Bextra scandal of 2009 was simply
their fourth off-label marketing fraud, but it was
not their last. In 2011, Pfizer was ordered to
pay federal charges for illegally marketing the
bladder drug Detrol.26 With the settlements
of Detrol and Bextra being only 2 years apart,
it is safe to conclude Pfizer did not learn their
lesson from punishments prior to Bextra, and
they certainly did not learn their lesson after,
either. Illegal advertisement and marketing are
the only crimes considered in this report, but
Pfizer’s list of crimes under product safety, fixed
pricing, bribery settlements, tax evasion, and
more, are not short either. Mike Loucks, the
federal prosecutor who oversaw the Bextra in-
vestigation worries that “the money is so great,
dealing with the Department of Justice may be
‘just the cost of doing business.’”27
As part of Pfizer’s Bextra settlement, and
in exchange for continual participation in Medi-
care, Medicaid, and other federal health care
programs, a five-year expansive corporate in-
tegrity agreement (CIA) was made between the
U.S. Department of Health and Human Services
to monitor future marketing activities.28 The
CIA included ongoing review procedures and
risk assessment. Pfizer pledged to create risk
mitigation plans for every pharmaceutical prod-
uct manufactured and an independent review
organization (IRO) to evaluate product develop-
ment and its promotions. Evidence of breach of
the CIA can lead to the exclusion from partic-
ipation of federal health programs which would
most likely collapse the company. To cure an
incompliance breach, Pfizer must comply to a
firm monetary penalty at upwards of $5,000 per
day the CIA agreement is broken. The govern-
ment used the Bextra settlement to set forth an
example of the rigorous government investiga-
tions and settlements for Pfizer’s peers in the
pharmaceutical industry.29
When the FDA tried to comply with Pfizer,
warning them to report serious and unexpected
side effects from produced drugs already on the
market, Pfizer said they would collaborate with
the FDA and “assured optimal surveillance and
reporting of post marketing adverse events.”30
However, the FDA later cited several reporting
lapses and even granted the company a waiver for
60 days to account for any complaints of Bex-
tra which Pfizer simply ignored.31 Therefore,
not only did Pfizer bear a minimal punishment
in committing numerous fraudulent crimes, but
they proved to have difficulty in adhering to
their punishment as well. As a result, not only
did other pharmaceutical companies learn how
to evade drastic corporate punishment, they
24“Settlement Agreement”, The United States Department of Justice, May 5, 2011,
https://www.justice.gov/sites/default/files/usaoedpa/legacy/2011/05/05/cephalon settlementagreement.pdf.
25Executive Office for United States Attorneys, “Health Care Fraud”, United States Attorney’s Bulletin, Jan-
uary 2009, 8-7
26Office of Public Affairs, “Pfizer to pay $14.5 Million for Illegal Marketing of Drug Detrol”, The United States
Department of Justice, October 21, 2011.
27Drew Griffin and Andy Segal, “Feds Found Pfizer too big to nail”, CNN Health, April 2, 2010,
http://www.cnn.com/2010/HEALTH/04/02/pfizer.bextra/.
28Erin Janssen, “Pfizer Settlement Makes History”, Journal of Health Care Compliance, December 2009, 33-36
http://search.proquest.com.proxy2.cl.msu.edu/docview/228005472/fulltextPDF/EC510EF85949489APQ/1?accountid=12598.
29Office of Public Affairs, “Justice Department Announces Largest Health care fraud Settlement in Its History”,
The United States Department of Justice, September 2, 2009, https://www.justice.gov/opa/pr/justice-department-
announces-largest-health-care-fraud-settlement-its-history.
30Gardiner Harris, “Pfizer Pays $2.3 Billion to Settle Marketing Case”, The New York Times, September 2,
2009, http://www.nytimes.com/2009/09/03/business/03health.html.
31Gardiner Harris, “Pfizer Pays $2.3 Billion to Settle Marketing Case”, The New York Times, September 2,
2009, http://www.nytimes.com/2009/09/03/business/03health.html.
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learned punishments do not have to be taken
seriously.
Societal Consequences
When a Fortune 500 company with severe
fraudulent activity escapes with minimal cor-
porate punishment, negative outcomes can be
anticipated. The following outlines arguments
of how this injustice and the structure of the
healthcare system causes all participants (e.g.
patients, doctors, pharmaceutical companies,
and even the healthcare industry at large) to
become “losers” to this technological system.
The CIA agreement was designed to foster
transparency of illegal medical promotions from
health care professionals. However, without
company compliance, monetary incentives are
too numerous and complicated to track down.
To capture a service fee like patient consulting
is easy, but for travel fees ancillary to research
services may only be stated in an expense report
system or a logistics vendor.32 Pharmaceutical
companies capitalize on the financial ambiguity
to pay doctors under the table for promotional
talks, speaker programs, research programs, and
even to conduct unethical clinical trials. How-
ever, even doctors accepting bribes cannot bear
all the faults of the corrupt industry either.
When a patient receives a prescription from a
physician, they trust that the doctor has done
extensive research about the drug. However,
bad clinical trials are regularly erased from the
report presented to doctors for the drug of inter-
est. Doctors spread their time thinly, in between
treating patients and updating themselves on the
latest medical practices. They do their best in
fulfilling the expectation to do in-depth research
on every drug they prescribe but faulty research
data makes this task difficult. When health care
professionals promote a drug, they trust that
their medical expertise conviction will provide
more benefit or relief to the patient than harm,
but sometimes the result cannot be all the fault
of the doctor.33
In a different perspective, pharmaceutical
companies may not be exploiting power, instead
the power is extended to them by the struc-
ture of the healthcare system. Thus, problems
may lie in the structure of the healthcare sys-
tem itself. The medical system is developed to
nurture one’s health. Typically, participants of
the system such as hospitals and pharmaceuti-
cal companies should also have the same chief
commitment. However, pharmaceutical compa-
nies are structured and run as businesses. The
purpose of the medical system conflicts with the
purpose of a business. The intent of a business
is to generate maximum profits by creating a
product better than the competition. The phar-
maceutical industry must juggle the responsibil-
ities of the health care industry and its financial
survival. In instances where the truth hinders
product marketing, it may be of more interest
to the company to prioritize the survival of the
company and contemplate about the quality or
harm of its products thereafter. Ideally, phar-
maceutical companies try to fulfill the purpose
of a business simultaneously with the purpose
of medicine, but realistically, one may be priori-
tized over the other.34
One may also argue there is only one winner
in this corrupt system, Pfizer; it is the only mem-
ber of this system securing profits. The power of
the company is simply too large for lawsuits to
affect their business. The profits the company
earns from unethical activities such as off label
marketing are only reimbursed fractionally from
these settlements. However, the company does
also bear social costs, especially the respect of
their name. Undeniably, pharmaceutical compa-
nies have created numerous beneficial products
devised to help improve the quality of life for pa-
tients. Yet, in public opinion surveys, they are
regularly critiqued as one of the least trusted in-
32Mark Ratner, “Crossing the line”, Nature Biotechnology 28 (2010): 1232-5
33Ben Goldacre, “Bad Pharma How Drug Companies Mislead Doctors and Harm Patients”, February 2013,
chapter 1 and 6
34Rudi Volti, Society and Technological Change. Worth Publishers, 2017.
35David Taylor, “The Pharmaceutical Industry and the Future of Drug Development”, Pharmaceuticals in the
32
dustries next to the nuclear industry.35 Like any
business, the public is the industry’s consumer
and source of profit. If the public continually
disproves of a company’s ethical conduct, there
may be other companies that produce similar
products which the public, as consumers, will
naturally explore as alternatives, and eventu-
ally, Pfizer’s loyal customers will abandon the
perilous company for products of a more honor-
able company.
Technological institutions, like the pharma-
ceutical industry, and inventions, like medica-
tions, are built with the intent of providing a
better quality of life for society. However, in
evading corporate punishment and harming mil-
lions, Pfizer is an example of how a technological
system may exploit power within a society and
warrants a re-evaluation of the true winners and
losers of this technological system.36
Ideally, all participants of this medical in-
dustry ought to benefit from one another. Phar-
maceutical companies, like Pfizer, can commer-
cialize medications aimed at improving a set of
patient symptoms derived from the best rec-
ommendation of a doctor. Patients get better
because their doctors prescribe a safe and suit-
able medication for their needs, and the phar-
maceutical company can turn a profit from their
reliable product. Everyone in the system wins.
However, patients do not get the help they seek
because doctors are prescribing harmful medica-
tions made by pharmaceutical companies with
narrow financial concerns. Patients do not get
better. The vow of a doctor practicing medicine,
to provide the best care for their patient, is bro-
ken. The profits of the pharmaceutical company
are returned in government settlements and their
tarnished name. The reputation of the pharma-
ceutical industry sustains irreparable damage.
Everyone in the system loses. Thus, in such
a complex system of medicine, regulation and
ethical reform should be established for pharma-
ceutical companies to restore the “winners and
losers” imbalance of the healthcare system and
public faith of the industry.
Solutions to Restoration
The pharmaceutical industry retains a bad
reputation in the public eye, and often with rea-
son, as exhibited from the events of the Bextra
case. However, restoring this reputation can
evoke necessary change in unethical corporate
practices and still support the company’s bank
account. A corporations reputation is an intan-
gible asset as valuable as the company’s worth.
With a good reputation, a company can fully
capitalize on its commercial goods while satisfy-
ing consumer demands. A pharmaceutical com-
pany’s reputation would depend on the experi-
ence that patients have had with the company’s
manufactured drugs and how the company is
portrayed in media and by word of mouth. Only
34% of patient groups surveyed from Europe and
North America believed major drug companies
had good reputation.37 The drug industry has
complicated and conflicting roles in improving
the lives of patients while maximizing profits
to fund further research and satisfy sharehold-
ers. Often, the pressure of how well their stock
performs puts the needs of patients secondary.
There is no cure-all to revitalize an industry’s
reputation, it takes time and a collective effort
towards change. The following offers some steps
to take in repairing this image.
One method to rebuild the pharmaceutical
industry’s reputation is to induce an ethical re-
form to put the needs of patients first. Medicine
was primarily developed for patients, not profits.
Major drug companies can collaborate with pa-
tient organizations to bridge the communication
gap between patient needs and listen to ways to
comply to them. Rather than promoting specific
products, this fosters trust in the company. Pro-
grams that build bonds with patients and their
physicians is a good place to start because physi-
cians hear the patient’s needs directly. As an
Environment, 2015, 1-33.
36Rudi Volti, Society and Technological Change. Worth Publishers, 2017.
37Mark Kessel, “Restoring the pharmaceutical industry’s reputation”, Nature Biotechnology 32 (2014): 983-990
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example, teaching patients about health issues,
like the harmful effects of when drug regimens
are not followed, provides a more constructive
educational experience than marketing products
to patients. Companies can develop adherence
programs for the drugs they produce to assist
in educating patients. Pfizer developed a social
media campaign in 2014 launching the hashtag
#FOGO, “fear of getting old”, to nurture the
Pfizer brand. Rather than promoting a prod-
uct, Pfizer simply stimulated conversations with
the public to listen to their worries. By refo-
cusing on patient needs, the company caters
to its biggest stakeholder, the consumers. A
restaurant known for its great service will nat-
urally attract more customers. If a pharmaceu-
tical company is strongly committed to provide
customers/patients exceptional care, generating
profits will follow. Serving the needs of ne-
glected patient groups, offering drugs with long
term needs instead of short term health benefits,
making drugs reasonably priced, and eliminat-
ing misleading marketing of drugs are a few
demands the public has for the industry. To
convince the public that pharmaceutical compa-
nies care about them is no easy task, but not
impossible. It will require a sense of urgency on
an industry-wide basis.38
The public also worries that drug companies
have no regard for patient safety. Implementing
data transparency to ensure patient safety and
generate honest conversations between health
care professionals and drug companies is one
way to combat this fear. Pharmaceutical com-
panies are known to only publish successful re-
search data and deleting the negative clinical
trials. Understandably company trade secrets
in formulating their drugs must remain confi-
dential to generate profits for their products,
but there are no excuses in withholding patient
safety data. Publishing all clinical data will
drastically improve clinical decisions and ties
back to the point of focusing on care of patients
rather than marketing drugs to them. Trans-
parency also changes behavior. ProPublica is
a publicly accessible website that tracks pro-
motional payments to health care professionals.
Drug companies have been forced to enter their
data into the database after numerous legal cases
were lost. After industry payments to doctors
have become more visible, such payments started
to decline. Data transparency, such as annual
financial reports and publishing negative clinical
trial data, will promote patient safety, reduce
unethical practices, and restore Big Pharma’s
good name.39 Brand reputation is a valuable
asset. If the pharmaceutical industry invests in
its reputation with the same care as it does its
other assets, positive change will certainly ensue.
No one individual, one patient, one doctor,
one company, can induce this change in Amer-
ica’s healthcare system. A collected effort from
all participants will only guarantee this stub-
born but necessary restoration. It starts from
the ground up: if pharmaceutical companies
take initiatives towards ethical reforms to prior-
itize the needs of patients before their financial
reports then patients and the public will be less
skeptical of the drug industry, and trust and
profits will naturally rise. The improvement
of data transparency builds a stronger bridge
of trust between health care professionals and
pharmaceutical companies. Physicians can rely
on the research of the drug and naturally further
support a high-quality product without the extra
illegal expenses of paying doctors as promotional
speakers for the company. These potential so-
lutions can restore the imbalance of “winners
and losers”, and help reduce immoral practices
within the healthcare system, an industry in-
tended to support and improve the value of our
lives.
Take Away
Drug companies, like Pfizer, have lost their
prestige in the public eye due to numerous du-
38Mark Kessel, “Restoring the pharmaceutical industry’s reputation”, Nature Biotechnology 32 (2014): 983-990
39Ben Goldacre, “Bad Pharma How Drug Companies Mislead Doctors and Harm Patients”, February 2013, 334-
379
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bious practices. Questionable practices such as
illegally marketing drugs at harmful dosages,
bribing health care professionals, evading corpo-
rate punishment at the time of prosecution, and
reluctance in adhering to the terms of corporate
punishment, are some examples seen in the Bex-
tra case that gave the pharmaceutical industry
its bad name. Although drug companies have
made many mistakes in the past, it is never too
late to change. Steps in repairing the reputa-
tion of the pharmaceutical industry, like putting
the needs of patients first and promoting data
transparency, benefits both the public and the
company. While listening to the demands of the
public and fostering public safety, the company
attracts more consumers by nurturing its brand
and improving its relationship with the public.
However, reputational change takes time and re-
quire industry wide effort. The public’s trust in
big pharma will worsen if a collected effort to fix
fundamental problems is not made which would
continue to harm the health of the public and
the industry.
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